Ametris
- Company typePrivate
- Founded2004
- HeadquartersPensacola, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
Ametris firmographics
Firmographics- Name
- Ametris
- Legal name
- Ametris, LLC
- Website
- https://ametris.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Ametris industry classification
Industry- Product category
- Clinical Trial Digital Health Technology
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Computer Systems Design Services (541512), Scientific Research and Development Services (5417)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG)
- akta.pro secondary industries
- Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management (HLACAOAI), Clinical Trial Management Systems (CTMS) (HLACAOAD), Safety/Pharmacovigilance (PV) & Clinical Safety Systems (HLACAOAH)
Keywords
Where Ametris is headquartered
LocationHeadquarters
- HQ city
- Pensacola
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ametris business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Wearable Device Sales: Sale of FDA-cleared medical-grade wearable devices including ActiGraph LEAP, CentrePoint Insight Watch, and wGT3X-BT for use in clinical trials and academic research
- Software Platform Subscription: Subscription access to CentrePoint platform for remote monitoring, data management, and analytics services
- Regulatory Science Services: Data analytics and regulatory science consulting services to support digital endpoint development and regulatory submissions
- DECODE Collaborations: Evidence-generation collaborations and exclusive biomarker IP licensing arrangements with pharmaceutical sponsors
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One time | Academic/Non-Profit Registration - Early Bird |
| Other | One time | Academic/Non-Profit Registration - Advance |
| Other | One time | Academic/Non-Profit Registration - Standard |
| Other | One time | Pharma/Industry Registration - Early Bird |
| Other | One time | Pharma/Industry Registration - Advance |
| Other | One time | Pharma/Industry Registration - Standard |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels9 records
Ametris product offering
Product offeringCore offering
Ametris provides an end-to-end digital health technology solution for clinical trials, combining FDA 510(k)-cleared, medical-grade wearable devices (ActiGraph LEAP, CentrePoint Insight Watch, wGT3X-BT) with the scalable CentrePoint remote monitoring platform powered by the Ametris Connect ecosystem. The company sells hardware, software subscriptions, and data analytics/regulatory science services to pharmaceutical sponsors, biotech companies, CROs, and academic researchers to enable continuous, objective measurement of digital outcomes across therapeutic areas.
Product overview
Ametris (formerly ActiGraph) provides an end-to-end digital health technology (DHT) solution combining medical-grade wearable devices, the scalable CentrePoint® remote monitoring platform powered by Ametris Connect™, and full-service operational and scientific support. The portfolio includes the ActiGraph LEAP® and CentrePoint® Insight Watch FDA-cleared wearable devices, ActiLife® data analysis software, and the Algorithm Marketplace for validated digital measures. Solutions span digital outcomes including sleep, physical activity, gait and mobility, vital signs, and cardinal symptoms, supported by data analytics and regulatory science services across therapeutic areas including cardiology, dermatology, obesity, oncology, respiratory, rheumatology, immunology, and neurology.
Differentiator
Problem solved
Functional benefit
Products and services
- CentrePoint® Platform Cloud-based data management platform for collecting, processing, and managing high-quality real-world data from wearable devices across clinical trials. Targeted at pharmaceutical sponsors and CROs running decentralized or hybrid clinical trials requiring centralized sensor data ingestion and management.
- Ametris Connect™ Platform
- CentrePoint® Insight Watch FDA-cleared, medical-grade wrist-worn wearable device with photoplethysmography (PPG) for continuous monitoring of vital signs, activity, and sleep in clinical trials. Used by pharmaceutical sponsors and academic researchers for remote vital sign monitoring.
- ActiGraph LEAP® FDA-cleared medical-grade wrist-worn wearable device combining accelerometer and PPG sensors for comprehensive digital health measurements in clinical research. Targeted at pharmaceutical sponsors and CROs conducting clinical trials requiring validated multimodal sensing.
- ActiGraph wGT3X-BT Research-grade actigraphy device for continuous monitoring of physical activity, sleep, and movement behaviors. Used by academic researchers and clinical trial sponsors for objective activity and sleep measurement.
- ActiLife® Software platform for data analysis, processing, and management of actigraphy data from Ametris wearable devices. Sold primarily to academic researchers and clinical trial teams for offline and research-grade data processing.
- Algorithm Marketplace Digital marketplace providing access to validated, regulatory-aligned algorithms for digital measures, enabling streamlined adoption in clinical development and regulatory submissions. Used by pharmaceutical sponsors and clinical trial teams to incorporate pre-validated digital endpoints into their studies.
- DECODE (Digital Endpoint Collaboration to Accelerate Outcome Development) Precompetitive collaboration programs bringing together multiple pharmaceutical sponsors to develop and validate digital endpoints in specific therapeutic areas (Obesity, Nocturnal Scratch/dermatology, CRS/oncology). Generates shared evidence, exclusive biomarker IP for participants, and regulatory engagement support.
Quantifiable outcome
- Combined eCOA and wearable platform reduces fragmented vendor approach in clinical trials
- +1 more outcomes
Companies that use Ametris
Customer profileNamed customers13 records
Segments4 records
Ideal customer profiles3 records
Ametris technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
Ametris partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Eli LillycoreDECODE: Obesity collaboration partner, working with Ametris on evidence generation and biomarker development for obesity therapeutics research
- RochecoreDECODE: Obesity collaboration partner, working with Ametris on evidence generation and biomarker development for obesity therapeutics research
- Novo NordiskcoreDECODE: Obesity collaboration partner, working with Ametris on evidence generation and biomarker development for obesity therapeutics research
- AstraZenecacoreDECODE: Obesity collaboration partner, working with Ametris on evidence generation and biomarker development for obesity therapeutics research
- Takeda PharmaceuticalscoreDECODE collaboration partner and conference participant; Head of Sensing and Measurement Ariel Dowling represents Takeda at ADDS events
- ParexelcorePlatinum level sponsor of ADDS conference; Parexel's Scientific Data Organization enables clinical research with wearables and sensors, with Sensor Solutions Director Nathan Noakes presenting at ADDS events
- IQVIAminorPlatinum sponsor of ADDS events; IQVIA's Patient Centered Solutions team helps companies design clinical trials that accurately reflect patient experience using digital endpoints
- Top 10 Global Pharma Companies (8 of top 10)corePartnerships with eight of the top ten global pharmaceutical companies through evidence-generation collaborations, exclusive biomarker IP licensing, and regulatory engagements
- Top 25 R&D Spenders (20 of top 25)corePartnerships with twenty of the top 25 R&D spending organizations through evidence-generation collaborations, exclusive biomarker IP licensing, and regulatory engagements
Scale indicators8 records
Recent moves8 records
Expansion highlights5 records
Ametris competitors and assessment
Company assessmentEmerging players
- Evidation Health: Evidation Health operates a connected health platform that generates real-world evidence from wearables and sensors for health outcomes research. Comparable in wearable-derived digital measurement and digital biomarker development for pharma and life sciences customers.
- Medable: Medable provides a decentralized clinical trial platform including eCOA, eConsent, and wearable/sensor data integration. Comparable in enabling pharma sponsors to operationalize DHT-enabled trials, though broader in scope than Ametris's wearable endpoint focus.
- Cytel: Cytel provides clinical trial analytics, statistical software (East), and biostatistics services with growing focus on digital endpoint strategy. Comparable in supporting regulatory-accepted clinical trial endpoints and serving pharma R&D organizations.
- PHAR (previously PhysIQ): PHAR (formerly physIQ) provides continuous biosensor data analytics and AI-driven digital biomarkers for clinical trials and healthcare. Comparable as a wearable/sensor digital biomarker platform serving pharma sponsors with regulatory-grade endpoints.
Broad incumbents
- Medidata (Dassault Systèmes): Medidata provides the Rave clinical cloud platform for eCOA, EDC, and decentralized clinical trials, and has been expanding into sensors/wearables integration. Comparable as a large incumbent in clinical trial data capture with growing DHT ambitions overlapping Ametris's wearable data platform.
- IQVIA: IQVIA is the world's largest CRO with a Patient Centered Solutions team that includes eCOA, digital endpoints, and wearable sensor strategy for clinical trials. Comparable as both a customer/partner and a broad incumbent offering overlapping digital endpoint capabilities.
- Signant Health: Parent company since May 2026, Signant Health is the leader in eCOA (electronic clinical outcome assessments) for clinical trials. Directly comparable as the eCOA counterpart to Ametris's wearable-based digital outcome measures, with overlapping pharma/biotech customer base and clinical trial technology focus.
Direct peers
- Clario: Clario (formed from the merger of ERT and CRF Health/Bioclinica) is a direct competitor in clinical trial technology, offering eCOA, cardiac safety, imaging, and increasingly wearable/respiratory sensor solutions. Most directly comparable end-to-end clinical trial technology peer with overlapping enterprise pharma customers.
- VivoSense: VivoSense develops wearable sensor-based digital clinical outcome assessments and validated digital endpoints for clinical trials, with a focus on regulatory-grade evidence. Closest direct peer to Ametris in the digital biomarker / wearable endpoint space for pharma trials.
- Koneksa Health: Koneksa Health provides digital biomarkers for clinical research using wearables and connected sensors, with a focus on respiratory, oncology, and rare disease trials. Comparable as a digital biomarker specialist serving pharma sponsors with overlapping therapeutic areas.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Ametris social profiles
Digital presenceAmetris compliance and trust
Trust signalCompliance7 records
Ametris financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ametris leadership team
Management profileNumber of profiles
Profiles2 records
Ametris funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ametris M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ametris
What does Ametris do?
Ametris provides an end-to-end digital health technology solution for clinical trials, combining FDA 510(k)-cleared, medical-grade wearable devices (ActiGraph LEAP, CentrePoint Insight Watch, wGT3X-BT) with the scalable CentrePoint remote monitoring platform powered by the Ametris Connect ecosystem. The company sells hardware, software subscriptions, and data analytics/regulatory science services to pharmaceutical sponsors, biotech companies, CROs, and academic researchers to enable continuous, objective measurement of digital outcomes across therapeutic areas.
Is Ametris a public or private company?
Ametris is a private company. It is classified as corporate owned and is currently operating.
When was Ametris founded?
Ametris was founded in 2004. It employs 51 to 100 people.
Where is Ametris based?
Ametris is headquartered in Pensacola, United States, in the North America region.
How does Ametris make money?
Four revenue lines are on record. Wearable Device Sales are the primary driver. The others are software Platform Subscription, regulatory Science Services and DECODE Collaborations.
Who are Ametris's main competitors?
Emerging players on record are Evidation Health, Medable, Cytel and PHAR (previously PhysIQ). Broad incumbents are Medidata (Dassault Systèmes), IQVIA and Signant Health. Direct peers are Clario, VivoSense and Koneksa Health.
Does Ametris have an API?
No public API is recorded for Ametris.
What industry is Ametris in?
Ametris's product category is Clinical Trial Digital Health Technology. Its primary akta.pro industry code is HLACAFAG, Medical-Grade Device Connectivity & Device Management (MDM), with a secondary code of HLACAOAI, Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management. Its NAICS code is 334510 and its SIC code is 3845.